title: Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine.
abstract: BACKGROUND
  Bendamustine, a bifunctional alkylating agent with anticipated purin-like properties is active in metastatic breast cancer (MBC) patients. This multicenter phase II trial defines the toxicity and activity of bendamustine in heavily pretreated patients.
  
  
  METHODS
  Fifty-one patients were included. Patients had a median number of 2 prior chemotherapeutic regimens for MBC (range 0-7) consisting of anthracyclines and taxanes: 26 patients (51%); anthracyclines: nine patients (17.6%); taxanes: seven patients (13.7%); others: five patients (9.8%). Bendamustine was administered four weekly at a dose of 120 mg/m(2) on days 1 and 2.
  
  
  RESULTS
  Fifty patients were assessable. Of total, 200 courses were administered. We observed no complete response (CR); 10 patients [20%; 95% confidence interval (CI): 10.0% to 33.7%] achieved a partial response (PR), 14 patients (28%) remained stable for at least 6 months resulting in a clinical benefit rate (CR + PR + stable disease) of 48% (95% CI: 33.7%to 52.6%). Median time to progression was 3.4 months (range 1-51.1). The median duration of remission was 6.6 months (range 1.8-48.7). The treatment was well tolerated with mainly hematologic toxic effects.
  
  
  CONCLUSIONS
  Single-agent bendamustine is an active treatment in patients with MBC independent of the previous treatment. The low toxicity profile favors its use as a single agent.
authors.affiliation: Department of Radiooncology, University of Tuebingen, Tuebingen, Germany. ursula.reichmann@med.uni-tuebingen.de
authors.forename: U
authors.initials: U
authors.lastname: Reichmann
authors.forename: C
authors.initials: C
authors.lastname: Bokemeyer
authors.forename: D
authors.initials: D
authors.lastname: Wallwiener
authors.forename: M
authors.initials: M
authors.lastname: Bamberg
authors.forename: J
authors.initials: J
authors.lastname: Huober
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D016879:Salvage Therapy
chemical_list: D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D000069461:Bendamustine Hydrochloride